Boston Scientific Co. (NYSE:BSX) Holdings Increased by Avestar Capital LLC

Avestar Capital LLC increased its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 40.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 17,381 shares of the medical equipment provider's stock after acquiring an additional 4,984 shares during the period. Avestar Capital LLC's holdings in Boston Scientific were worth $1,552,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. MGB Wealth Management LLC increased its stake in Boston Scientific by 3.8% during the fourth quarter. MGB Wealth Management LLC now owns 7,073 shares of the medical equipment provider's stock worth $633,000 after acquiring an additional 262 shares during the last quarter. MTM Investment Management LLC increased its position in Boston Scientific by 2.7% during the 4th quarter. MTM Investment Management LLC now owns 5,772 shares of the medical equipment provider's stock worth $516,000 after purchasing an additional 150 shares in the last quarter. TFC Financial Management Inc. raised its holdings in Boston Scientific by 308.8% in the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 210 shares during the period. Consolidated Planning Corp lifted its position in Boston Scientific by 2.1% during the fourth quarter. Consolidated Planning Corp now owns 48,773 shares of the medical equipment provider's stock valued at $4,356,000 after buying an additional 1,018 shares in the last quarter. Finally, Clarity Capital Partners LLC grew its stake in Boston Scientific by 26.5% during the fourth quarter. Clarity Capital Partners LLC now owns 3,156 shares of the medical equipment provider's stock worth $282,000 after buying an additional 661 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Boston Scientific

In related news, Director Edward J. Ludwig sold 12,000 shares of Boston Scientific stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $105.48, for a total value of $1,265,760.00. Following the sale, the director now directly owns 24,398 shares in the company, valued at $2,573,501.04. This trade represents a 32.97 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Arthur C. Butcher sold 14,010 shares of the firm's stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the completion of the sale, the executive vice president now owns 978 shares in the company, valued at $87,306.06. The trade was a 93.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 87,326 shares of company stock worth $8,673,948 over the last ninety days. Company insiders own 0.50% of the company's stock.

Analyst Upgrades and Downgrades

BSX has been the topic of several recent research reports. Raymond James lifted their target price on shares of Boston Scientific from $119.00 to $122.00 and gave the company a "strong-buy" rating in a report on Thursday, February 6th. TD Cowen raised their price objective on Boston Scientific from $100.00 to $110.00 and gave the company a "buy" rating in a research report on Thursday, December 12th. StockNews.com raised Boston Scientific from a "hold" rating to a "buy" rating in a research report on Wednesday, January 29th. Wells Fargo & Company raised their target price on Boston Scientific from $100.00 to $118.00 and gave the company an "overweight" rating in a report on Thursday, February 6th. Finally, UBS Group boosted their price target on Boston Scientific from $105.00 to $130.00 and gave the stock a "buy" rating in a research report on Friday, February 7th. One analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Boston Scientific currently has an average rating of "Buy" and an average price target of $107.39.

Boston Scientific Stock Performance

Shares of NYSE BSX traded up $0.06 during trading on Monday, reaching $106.20. The stock had a trading volume of 3,966,417 shares, compared to its average volume of 6,179,673. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. The stock has a market cap of $156.51 billion, a PE ratio of 84.96, a P/E/G ratio of 2.79 and a beta of 0.80. Boston Scientific Co. has a one year low of $65.33 and a one year high of $107.17. The firm's 50 day moving average price is $96.44 and its two-hundred day moving average price is $88.39.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 18.11%. On average, research analysts forecast that Boston Scientific Co. will post 2.83 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.